IPAD also identified heat-shock protein regulation as a potential therapeutic strategy as noted by the ability of the Hsp90 inhibitor geldanamycin to promote ErbB2 degradation in SKBR breast cancer cells [42]. This evidence concerns the gene ERBB2 and breast cancer.